GLP-1 Side Effects Compared: Semaglutide vs Tirzepatide
Released · Last reviewed
Both semaglutide and tirzepatide most commonly cause gastrointestinal side effects — nausea, diarrhea, vomiting, constipation. Rates are broadly similar; slow dose titration is the main strategy to reduce them.
- GI effects (nausea, diarrhea, vomiting, constipation) are the most common for both drugs.
- Side effects are usually worst during dose escalation and often ease over time.
- Both carry a boxed warning for thyroid C-cell tumors based on rodent studies.
- Slow titration is the primary evidence-based strategy to reduce GI effects.
The common side effects
Both semaglutide and tirzepatide share a side-effect profile dominated by the gastrointestinal tract: nausea, diarrhea, vomiting, constipation, and abdominal discomfort. These are the effects most people experience, and they are usually most intense during dose escalation before easing as the body adjusts.
Across the STEP and SURMOUNT trials, the majority of participants reported at least one GI effect, but most were mild to moderate and relatively few discontinued because of them.
Do they differ between the drugs?
Head-to-head, the side-effect profiles are broadly similar. Both drugs work through GLP-1 receptor activation, which drives the GI effects, and tirzepatide's additional GIP activity does not appear to dramatically change the tolerability picture for most people.
Some individuals tolerate one molecule better than the other, which is not fully predictable in advance. If side effects on one are intolerable, a clinician may consider switching, but there is no universal rule that one is gentler.
| Effect | Frequency | Usually worst when |
|---|---|---|
| Nausea | Very common | Dose escalation |
| Diarrhea | Common | Dose escalation |
| Constipation | Common | Ongoing |
| Vomiting | Common | Dose escalation |
The serious warnings
Both carry a boxed warning for thyroid C-cell tumors, based on rodent studies; they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both list a risk of pancreatitis, gallbladder problems, and, rarely, more serious reactions. These are uncommon but important, and any severe abdominal pain, persistent vomiting, or signs of an allergic reaction warrant urgent medical attention.
These warnings apply to the FDA-approved products; compounded formulations carry the same molecular risks without formulation-specific safety data.
| Warning | Note |
|---|---|
| Thyroid C-cell tumors | Boxed warning; contraindicated with MTC/MEN2 history |
| Pancreatitis | Uncommon; seek care for severe abdominal pain |
| Gallbladder | Risk with rapid weight loss |
Managing side effects
The primary evidence-based strategy is slow dose titration, which is exactly why both drugs are escalated gradually rather than started at full dose. Eating smaller meals, avoiding high-fat foods, and staying hydrated are commonly advised, though the strongest evidence supports the titration schedule itself.
Persistent or worsening symptoms should be reported to the prescribing clinician rather than managed alone, and dose adjustments are a clinical decision. Do not self-adjust dosing to control side effects.
Frequently asked questions
Which has fewer side effects, semaglutide or tirzepatide?
Their profiles are broadly similar, both dominated by GI effects. Some people tolerate one better, but there is no universal rule that either is gentler.
Do side effects go away?
They are usually worst during dose escalation and often ease as the body adjusts. Slow titration is designed to reduce them.
When should I seek medical care?
For severe abdominal pain, persistent vomiting, signs of an allergic reaction, or any severe or worsening symptom, seek urgent care.
Sources
- Clinical trials via NEJM.
- STEP and SURMOUNT trial safety data.
- FDA — human drug compounding and GLP-1 status.
The numbers behind this page
Three questions to ask before acting on this entry
Every price quoted in this entry comes from the programme's own pricing page and carries the date it was captured.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
At the October 15, 2026 semaglutide median of $99 a month, medication alone runs $1,188 a year, $3,564 over three and $5,940 over five. At $279, the highest all-in rate we read, the same horizons are $3,348, $10,044 and $16,740.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.